Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Placebos

SSRIs and SNRIs for paediatric psychiatric disorders yield only small benefit over placebo

The use of selective serotonin reuptake inhibitors (SSRIs) and serotonin–norepinephrine reuptake inhibitors (SNRIs) in paediatric psychiatric disorders is still under debate.

In a meta-analysis in JAMA Psychiatry (online, 30 August 2017), researchers looked at data from 36 randomised trials of SSRIs and SNRIs involving 6,778 young people with depressive disorder, anxiety disorder, obsessive-compulsive disorder or post-traumatic stress disorder[1].

They found that SSRIs and SNRIs were significantly more effective than placebo. However, the effect sizes were small and varied between conditions. They also found that placebo effect plays a substantial role in the efficacy of antidepressants, particularly in depressive disorder, with the least placebo effect seen in anxiety disorder.

Noting that both drug classes were associated with an increased risk of severe adverse events, the researchers said the cost–benefit balance of these drugs should be cautiously considered.

Citation: Clinical Pharmacist DOI: 10.1211/CP.2017.20203822

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Child in a corner with his eyes covered

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.